![Lomustine's path from unavailable but cheap to plentiful but expensive Needed: A better manufacturing method](https://cdn.cancerletter.com/media/2019/11/Lomustine-web.jpg)
![Lomustine's path from unavailable but cheap to plentiful but expensive Needed: A better manufacturing method](https://cdn.cancerletter.com/media/2019/11/Lomustine-web.jpg)
Cover Story
Lomustine, a.k.a. CCNU, is an old cancer drug.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI Trials for November 2019
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- When tobacco companies sponsored the Olympics
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Jonathan Gerber named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access